// Biotech and Pharma Therapeutics
Hate exercise? Neuroscience maps the routine your personality will love
July 8, 2025 / personality-based fitness / neuroticism stress relief / exercise psychology / tailored workout plans / physical activity adherence
Exercise enjoyment and adherence improve when matched to personality traits, with notable stress reduction in neurotic individuals. Tailored activity plans may enhance fitness outcomes and long-term physical activity engagement, especially in sedentary populations.
For patients with complex care needs, AI is helpful—but the human touch is irreplaceable
July 8, 2025 / AI in primary care / chronic condition management / patient-centered technology / clinician-patient relationship / digital health equity
AI tools may enhance care for patients with multiple chronic conditions, but clinicians stress the irreplaceable value of human interaction. Safe integration requires patient-centered design, transparency, EHR compatibility, and clarity on medicolegal responsibilities.
Alzheimer’s doesn’t strike at random: These 4 early-warning patterns tell the story
July 7, 2025 / Alzheimer’s prediction / diagnostic pathways / cognitive decline risk / early detection strategies / personalized prevention
UCLA researchers identified four diagnostic pathways—mental health, encephalopathy, mild cognitive impairment, and vascular disease—that predict Alzheimer’s more accurately than single risk factors, enabling earlier detection, risk stratification, and personalized prevention strategies across diverse populations.
Digital platform supports personalized diet goals in primary care for diabetes
July 9, 2025 / diabetes nutrition tools / personalized diet goals / digital health platform / primary care innovation / type 2 diabetes management
Nutri, a digital platform used in primary care, effectively supports personalized diet goal-setting for patients with type 2 diabetes, demonstrating high usability and engagement, particularly in underserved populations, and showing promise for improving nutrition counseling and care outcomes.
MedCity Pivot Podcast: Why Blood Pressure Monitoring Is Due for A New Era
July 9, 2025 / hypertension monitoring / continuous blood pressure / wearable health tech / CoraVie Medical innovation / cardiovascular care advancement
CoraVie Medical’s implantable device offers continuous, accurate blood pressure monitoring—capturing critical fluctuations and nighttime data—to improve hypertension diagnosis, treatment personalization, and clinical decision-making, addressing limitations of traditional cuff-based methods.
// 4th Industrial Revolution
Russian researcher strategizes on collaboration with China over healthcare AI
July 2, 2025 / healthcare AI collaboration / Russia China partnership / digital medicine strategy / AI diagnostics innovation / international health data exchange
A Russian academic outlines strategic collaboration with China on healthcare AI, emphasizing joint innovation in diagnostics and telemedicine, while calling for data-sharing agreements and bilateral research centers to overcome regulatory and communication barriers in advancing digital medicine.
Artificial Intelligence Integration with Epic EHR: Promise and Practicalities
July 9, 2025 / Epic EHR integration / healthcare AI adoption / clinical decision support / medical data governance / digital health infrastructure
Integrating AI into Epic EHR systems presents major opportunities for clinical improvement but requires robust infrastructure, data governance, interoperability planning, and clinician-centered design to ensure adoption, security, and measurable impact on patient outcomes and operational efficiency.
AI system estimates bone density using routine X-ray images
July 9, 2025 / bone density AI / osteoporosis detection / X-ray diagnostics / osteopenia screening / orthopedic imaging innovation
A new AI-assisted system accurately estimates bone mineral density from routine X-rays, demonstrating high sensitivity and specificity for detecting osteopenia and osteoporosis in the lumbar spine and femur, potentially enabling earlier, non-invasive screening for bone health issues.
Most Effective Tools and Technologies in Providing Real Time Insights Into Financial Performance and Key RCM Metrics
July 9, 2025 / revenue cycle management / real-time financial insights / healthcare BI tools / AI in RCM / EHR data integration
Real-time revenue cycle insights rely on integrated BI tools, AI analytics, and cloud infrastructure to improve financial performance, reduce claim denials, and support proactive decision-making, with seamless EHR integration critical for aligning clinical and financial operations.
Artificial intelligence tracks aging and damaged cells through high resolution imaging
July 8, 2025 / cellular aging AI / senescence tracking tool / nuclear morphometric pipeline / regenerative medicine imaging / AI in tissue repair
NYU researchers developed an AI-driven tool using nuclear morphometrics from high-resolution imaging to track senescent cells. This innovation enables precise monitoring of aging, injury, and disease-related tissue changes, advancing regenerative medicine and senolytic therapy development.
// Business & Markets
Will medtech M&A pick back up in the second half?
July 9, 2025 / medtech M&A trends / healthcare acquisitions 2025 / medical device deals / strategic healthcare investment / surgical robotics growth
Medtech M&A activity slowed mid-2025 due to economic uncertainty and tariff concerns but is expected to rebound as companies refocus on strategic growth. Key sectors like surgical robotics and diabetes remain high-priority for targeted, innovation-driven acquisitions.
Pfizer’s Sally Susman to step down at year’s end amid broader restructuring
July 8, 2025 / Pfizer leadership change / Sally Susman departure / pharmaceutical restructuring / COVID vaccine communications / corporate affairs transition
Pfizer’s EVP Sally Susman will step down amid corporate restructuring that redistributes communications and policy functions across the organization. Her departure marks a shift in leadership following her pivotal role in Pfizer’s COVID-19 vaccine communications strategy.
Revolution lines up Iambic’s AI platform in discovery collab worth up to $25M
July 9, 2025 / AI drug discovery / RAS cancer therapy / oncology collaboration / protein-ligand modeling / Revolution Iambic partnership
Revolution Medicines and Iambic Therapeutics have partnered to apply AI-driven drug discovery to difficult oncology targets, leveraging Iambic’s neural network models and Revolution’s proprietary molecular data to accelerate development, particularly for RAS-driven cancers like non-small cell lung and pancreatic cancers.
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
July 9, 2025 / ENPP1 inhibitor / hypophosphatasia treatment / preclinical asset sale / Rallybio Recursion deal / rare disease drug development
Rallybio will sell its stake in REV102, an ENPP1 inhibitor for hypophosphatasia, to Recursion for up to $25M. The preclinical asset advances toward IND-enabling studies, with potential milestones and royalties tied to future development and commercialization.
Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma
July 9, 2025 / COPD treatment innovation / Merck Verona acquisition / Ohtuvayre respiratory drug / dual PDE inhibitor / cardio-pulmonary pipeline
Merck will acquire Verona Pharma for $10B, gaining Ohtuvayre, a first-in-class COPD drug with dual anti-inflammatory and bronchodilatory action. The deal strengthens Merck’s cardio-pulmonary pipeline and offsets Keytruda’s looming patent loss, with potential expansion into other respiratory conditions.
// Legal & Regulatory
Lilly gets FDA OK of modified dosing for Alzheimer’s drug
July 9, 2025 / Kisunla FDA approval / Alzheimer’s drug dosing / ARIA brain swelling / amyloid plaque treatment / Eli Lilly Alzheimer’s therapy
The FDA approved a modified dosing schedule for Lilly’s Alzheimer’s drug Kisunla, significantly reducing ARIA-related brain swelling. The adjustment may improve safety, physician confidence, and adoption of this amyloid-targeting therapy amid ongoing debates on risk, benefit, and cost.
Novo Nordisk files high-dose Wegovy in EU
July 9, 2025 / Wegovy high dose / obesity drug competition / GLP-1 weight loss / Novo Nordisk EMA filing / semaglutide versus Zepbound
Novo Nordisk filed for EU approval of a higher 7.2mg dose of Wegovy, showing enhanced weight loss in obesity and type 2 diabetes patients. The strategy aims to counter Eli Lilly’s Zepbound amid intensifying competition in the obesity market.
Agencies up efforts to cut animal testing
July 9, 2025 / FDA animal testing / NIH alternative methods / non-animal research / regulatory science innovation / biomedical ethics workshop
The FDA and NIH hosted a workshop focused on reducing animal testing through novel methodologies, reflecting growing regulatory commitment to alternative models in biomedical research. International experts discussed implementation strategies, successes, and ongoing challenges in this evolving scientific landscape.
Dizal to challenge J&J with FDA approval for lung cancer drug Zegfrovy
July 7, 2025 / Zegfrovy FDA approval / EGFR exon 20 NSCLC / oral lung cancer therapy / Dizal Pharmaceuticals breakthrough / targeted cancer treatment
The FDA granted accelerated approval to Dizal’s Zegfrovy, the first oral treatment for NSCLC with EGFR exon 20 insertions post-chemotherapy. Backed by strong response data, Zegfrovy offers a convenient alternative to existing therapies and advances personalized lung cancer care.
Samsung Deepens Healthcare Bet With Xealth Acquisition
July 8, 2025 / Samsung digital health / Xealth acquisition healthcare / clinical workflow integration / home health monitoring / provider digital adoption
Samsung will acquire digital health platform Xealth to integrate its devices into clinical workflows and expand its presence in home health monitoring. The move supports growing provider-driven adoption of digital tools across major U.S. health systems.
// Research & Development
MIT develops implantable device to automatically release emergency glucagon
July 9, 2025 / implantable glucagon device / emergency diabetes treatment / hypoglycemia prevention technology / MIT drug delivery system / wireless medical implants
MIT researchers have developed an implantable, wireless-triggered device that releases powdered glucagon during severe hypoglycemia in Type 1 diabetes. The device offers rapid, automated intervention and may expand to emergency drug delivery, such as epinephrine for anaphylaxis or cardiac events.
Innovative genome editing approach could be the key to lifelong effective weight management
July 9, 2025 / genome editing obesity / Exenatide gene therapy / weight loss innovation / sustained drug delivery / GLP-1 genetic treatment
Researchers at the University of Osaka developed a genome editing strategy that enables liver cells to continuously produce Exenatide, offering a potential one-time treatment for obesity and prediabetes by replacing chronic injections with sustained in-body drug production.
As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
July 9, 2025 / cancer vaccine TG4050 / individualized immunotherapy / neoantigen therapy manufacturing / AI in drug production / Transgene oncology pipeline
Transgene advances its individualized cancer vaccine TG4050 into phase 2 trials, while ramping up manufacturing capabilities under new CTO Simone Steiner. The company leverages AI and automation to streamline production, aiming to scale precision immunotherapy despite previous clinical setbacks.
First subject dosed in Upstream Bio’s Phase II trial of verekitug for COPD
July 9, 2025 / COPD clinical trial / verekitug TSLP antibody / biologic respiratory therapy / Upstream Bio COPD / Phase II VENTURE study
Upstream Bio has initiated its Phase II VENTURE trial of verekitug, a TSLP receptor-targeting biologic, in moderate-to-severe COPD patients. The study evaluates dosing efficacy, exacerbation reduction, and lung function, potentially offering a novel, less frequent biologic treatment option.
MIT scientists just supercharged the enzyme that powers all plant life
July 8, 2025 / rubisco enzyme engineering / photosynthesis enhancement / crop yield innovation / directed evolution MIT / sustainable agriculture biotech
MIT scientists enhanced rubisco’s efficiency by 25% using a novel directed evolution method, potentially improving photosynthesis in crops. This approach could reduce energy loss from photorespiration and offer long-term gains in agricultural productivity and food system resilience.
// Politics
Justice Department issues subpoenas to clinics and drugmakers over gender-affirming care
July 9, 2025 / gender-affirming care subpoenas / DOJ transgender healthcare / drug marketing investigation / gender care regulation / transgender medical access
The U.S. Department of Justice has subpoenaed nearly 20 clinics and drugmakers involved in gender-affirming care, focusing on drug marketing and regulatory compliance. This escalates federal scrutiny amid broader legal and political actions targeting transgender healthcare access.
Supreme Court Suspends Injunction Preventing RFK Jr.’s HHS Cuts
July 9, 2025 / HHS workforce reduction / Supreme Court RFK Jr. / federal health reorganization / Trump executive order / public health agency cuts
The U.S. Supreme Court has allowed the Trump administration’s plan to cut over 10,000 HHS jobs to proceed, reversing a prior injunction. Legal challenges persist, raising concerns over executive authority and impacts on public health infrastructure.
Senate committee advances Susan Monarez to be Trump’s CDC director
July 9, 2025 / Susan Monarez CDC / Senate confirmation CDC / Trump CDC nominee / CDC leadership change / public health policy
The Senate health committee advanced Susan Monarez’s nomination as CDC director, marking the first time the role undergoes Senate confirmation under a 2023 law. Monarez, currently acting director, faces full Senate approval amid partisan division.
Trump says copper, pharmaceutical tariffs coming ‘very soon’
July 8, 2025 / pharmaceutical import tariffs / Trump drug policy / U.S. pharma supply chain / domestic drug manufacturing / Section 232 investigations
President Trump announced upcoming tariffs of up to 200% on pharmaceutical imports, allowing one year for companies to adjust. The move follows ongoing investigations into supply chain vulnerabilities and aims to boost domestic drug manufacturing amid growing trade policy shifts.
Court orders HHS to restore webpages related to ‘gender ideology’
July 8, 2025 / gender ideology ruling / HHS website restoration / Trump executive order / clinical care disruption / gender-affirming care policy
A federal court ordered HHS to restore web content removed under Trump’s executive order targeting “gender ideology,” citing harm to clinical care. The ruling allows future content removal but requires adherence to proper legal and procedural processes.